Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Cited by
Items 401–478 of 478
Ng, K.-L. (2018) · The HKU Scholars Hub (University of Hong Kong) · doi:10.5353/th_991044122098003414 · Cited by 1
DNA damage, repair and mutational spectrum
Bian, K. (2019) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-bian-ke-2019
Immune Heterogeneity of IDH Glioma Subtypes
Richardson, L. G. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Ocsenas, O. (2020) · TSpace (University of Toronto)
SOHO State of the Art Updates and Next Questions: IDH Inhibition
Dragani, M., & de Botton, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.004
Epigenetic Targets in the Treatment of cancer
Codacci-Pisanelli, G. (2017) · Novel Approaches in Drug Designing & Development · doi:10.19080/napdd.2017.01.555567
Faculty Opinions recommendation of Cutting edge molecular therapy for acute myeloid leukemia.
Liu, M. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738375855.793584684
Protein Moonlighting and Human Health and Idiopathic Human Disease
Henderson, B. E., Fares, M. A., & Martin, A. C. R. (2016) · Wiley eBooks · doi:10.1002/9781118952108.ch7
DNA Methylation as a Biomarker in Cancer
Fukushige, S., & Horii, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-7744-6_45-1
Intermediate and Malignant Cartilaginous Tumors of Bone
(2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37678-5.50190-0
Highlights from the Literature
(2019) · Neuro-Oncology · doi:10.1093/neuonc/noz059
Faculty Opinions recommendation of Epigenetic plasticity and the hallmarks of cancer.
Copeland, R. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727820917.793555741
Treviño, L. S., & Walker, C. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95610-1
Choate, K. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726744181.793558674
Qin, Q., Mao, W., Zhang, X., & Wang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1989629/v1
Bajia, D., Ambe, G. N. N. N., & Derwich, K. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1622
Agarwal, A., Jain, M., Kushwaha, R., Tewari, S., Nayak, S., Verma, N., Tripathi, A. K., & Kumar, A. (2023) · International Journal of Medical Science and Diagnosis Research · doi:10.32553/ijmsdr.v7i1.974
“27 | P a g e oncometabolite 2 D hydroxyl glutarate(D2HG)5,6,7 [14,15,16].”
BackgroundGene Expression Under Combined Hypoxia And Acidosis In Chondrosarcoma
Stacey, M. W., Vangjeli, K., & Osgood, C. J. (2023) · International Journal of Orthopaedics Research · doi:10.33140/ijor.06.02.04
MRI: An important biomarker for radiomics study of brain cancer using machine learning
Majhi, V., & Paul, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18508-3.00004-8
Nandini, C., Snehitha, M. V., Meghana, A. S., Satvika, K., Anvesh, G., Babu, P. S., & Sankar, P. R. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i03.019
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212775
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212772
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212778
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212751
Zhu, Z., Yang, L., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212769
Varachev, V. O., Guskov, D. A., Shekhtman, A. P., Рогожин, Д. В., Polyakov, S. A., Chudinov, A. V., Zasedatelev, A. S., & Nasedkina, T. V. (2023) · Биоорганическая химия · doi:10.31857/s0132342323050093
Impact du R-2HG sur l'environement immunitaire des gliomes IDH1 mutés
Richard, Q. (2022) · theses.fr (ABES) · doi:10.70675/028d6799zbec4z48eez9deaz56fa6f14fd6b
Epigenetic biomarkers in personalized medicine
Stoccoro, A., Coppedè, F., & Migliore, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00018-1 · Cited by 1
Weigel, C., Klimaszewski, H., Addissie, S., Schlotter, S. Y., Tounkara, F., Dugan, J. P., Haverkos, B. M., Villagomez, L., Lustberg, M. E., Porcu, P., et al. (2024) · medRxiv · doi:10.1101/2024.08.17.24311219
“We next validated these findings by establishing a second model of TET deficiency that relies on overexpression of mutant isocitrate dehydrogenase 1 (IDH1 R132H) which impairs all three TET family members by generating an alternative metabolite, alpha-hydroxyglutatrate (35).”
Filipowicz, A. R., Chen, Q., & Allard, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00139-x
Pasquier, F., & de Botton, S. (2024) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2024.20.1.6
“22–24 α -KG is a cofactor for more than 60 α -KG- dependent dioxygenases ( α -KGDDs) involved in a wide range of cellular processes, such as hypoxia, angiogenesis, maturation of collagens of the extracellular matrix, DNA repair and regulation of epigenetics.”
Impact of D-2HG on the Tumor Microenvironment of IDH-mutated Gliomas
Laurenge, A. (2024) · theses.fr (ABES) · doi:10.70675/4c8abeaez46dfz40bdz8c7bzffd11e8e6b36
Mutant IDH impairs chromatin binding by PDGFB to promote chromosome instabilityPreprint
Curry, R. N., McDonald, M. F., He, P., Lozzi, B., Ko, Y., O’Reilly, I., Rosenbaum, A., Kwon, W., Fahim, L. E., Marcus, J. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639365
In vivo and in vitro analysis of functional effects of the SDHD H50R variant
Priya, S., Chakravarthy, K., Ziegler, E., Vesco, X., LaPerle, K., Zhang, X., & Kirschner, L. S. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0337
Pharmacoepigenetics of systemic lupus erythematosus
Hedrich, C. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00036-0
Navarro, L., Megías, J., Salazar-Saura, I., Sánchez-Pardo, M., Roselló-Sastre, E., & San‐Miguel, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311483
“The neomorphic activity of the mutant IDH1/2 enzymes produces this metabolite, which promotes a hypermethylated state of DNA and histones [7,17], potentially favoring the occurrence of R273C.”
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Chien, K. S., Loghavi, S., Sasaki, K., McCue, D. A., Daver, N. G., Kadia, T. M., Ravandi, F., Short, N. J., Issa, G. C., Bravo, G. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.001
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212760
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24779207
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24779363
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26651274
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212754
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212766
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212763
Zhu, Z., Lan, Y., Wang, L., Ge, J., Wang, J., Liu, F., He, Z., Zhang, H., Luo, M., Lin, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13212757
Ortíz-Meza, I. A. (2020) · El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León)
THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA
Demir, H., Özdemir, Ç., Baykara, M., Demirci, A., Beypınar, İ., Davarcı, S. E., Özdemir, C. Y., Çulha, Y., & Arıöz, D. T. (2026) · Kocatepe tıp dergisi. · doi:10.18229/kocatepetip.1576255
Wang, Z. L. (2026) · Theoretical and Natural Science · doi:10.54254/2753-8818/2026.pj31787
Novel amphiphilic dendrimers as nanovectors for siRNA delivery
Wang, Y. (2014) · theses.fr (ABES) · doi:10.70675/4ee48c7dze7a0z42d6z96d1z5ac9b5f4c811
Hepatitis C virus-induced reprogramming of glutamine metabolism
Levy, P. L. (2014) · theses.fr (ABES) · doi:10.70675/929a33efz4d38z446cz8ed0z4114fa34d6ea
Etude de la reprogrammation métabolique de l' adénocarcinome canalaire pancréatique
Olivares, O. (2015) · theses.fr (ABES) · doi:10.70675/ef2c6a2czab6dz4a68z8004z1ade8605dadc
Rôle de E4F1 dans la régulation de l'homéostasie des cellules cancéreuses
Houlès, T. (2015) · theses.fr (ABES) · doi:10.70675/e8fee4b0z4774z4e2cz8af0z6ec05b379c25
Ghedira-Hellara, D. (2018) · theses.fr (ABES) · doi:10.70675/8f849fe0z0ccdz4720za9c4zdd63d866bf61
Rôle de PCNA cytoplasmique dans la survie cellulaire
Ohayon, D. (2016) · theses.fr (ABES) · doi:10.70675/28be1a2dzb11cz4ee3z904az5dc0a03c2b67
Identification and Characterization of New Therapeutic Targets in Acute Myeloid Leukemia
Benajiba, L. (2018) · theses.fr (ABES) · doi:10.70675/76ba4ad8zc347z4443za6a1zc67553b19089
L'épigénétique comme modulateur de l'expression de hTERT dans les lymphomes T cutanés
Chebly, A. (2020) · theses.fr (ABES) · doi:10.70675/9464cf37z20b3z4d7cz9053z3a974daff409
Identification de nouvelles approches thérapeutiques pour les lymphomes T périphériques
Krug, A. (2023) · theses.fr (ABES) · doi:10.70675/a7d03ecfz08c1z4eb2z8979z0a3888d49669
Etude de l'hétérogénéité du microenvironnement et des cellules tumorales dans le lymphome TFH
Mboumba, D. L. (2024) · theses.fr (ABES) · doi:10.70675/ab609d7azbd90z40daza2b9za9670f82c1f5
2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation
Thamim, M., Dhabal, D., Balamurali, M. M., & Thirumoorthy, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1791517
“Mutations in IDH enzymes represent critical oncogenic events and are widely reported across various malignancies (37).”
Biomarkers of Cancer Metabolism and Therapeutic Response
Tanzadehpanah, H., Firouzjaei, A. A., Izadi, N., Mansourian, M., Esfandiari, A. H., Mokhtari, K., Forouzanfar, F., Afkhami, H., Reza, M. A. S., Sheykhhasan, M., et al. (2026) · Cancer treatment and research · doi:10.1007/978-3-032-21861-2_10
Metabolic signatures of triple-negative breast cancer
Pusalkar, G., Madamakki, R., Chakraborty, P., Parodi, A., & Lopus, M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12292-x
“Elevated D2HG levels can therefore serve as a biomarker for IDH-mutant cancers, and mutant IDH enzymes are being targeted therapeutically to reduce D2HG and counteract its oncogenic effects [ 27].”
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197396
“Accumulation of D-2-hydroxyglutarate promotes epigenetic dysregulation, impaired cellular differentiation, metabolic reprogramming, and tumorigenic plasticity, providing a strong rationale for selective IDH1 inhibition [49,202,204,207].”
FOXJ1, a novel oncosupressor transcription factor in a subgroup of PDAC patients
Terrasi, A. (2024) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.34336
Yanuck, S. F., & Alexis, N. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1929067
BindingDB (2023) · UC San Diego · doi:10.7270/q2rj4pcp
BindingDB Entry 50013577: Discovery and Optimization of 2
BindingDB (2022) · UC San Diego · doi:10.7270/q2ff3x3s
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.